Alexander G J, Fagan E A, Hegarty J E, Yeo J, Eddleston A L, Williams R
J Med Virol. 1987 Jan;21(1):81-7. doi: 10.1002/jmv.1890210111.
A randomised, controlled trial comparing acyclovir, 45 mg/kg/day as a continuous IV infusion for 28 days, with no other therapy, was carried out in 30 stable HBsAg carriers seropositive for HBeAg for more than 6 months. Twenty-eight had hepatitis B virus DNA-polymerase activity and/or hepatitis B virus DNA in serum at entry into the study. There were no significant adverse effects of therapy. At 12 months, seroconversion from HBeAg to anti-HBe had occurred in four of 15 treated patients, one of whom had also developed anti-HBs, compared with only one of 15 in the untreated group (95% confidence limits 12% and 51%). Seroconversion from HBeAg to anti-HBe was accompanied by return of serum liver function tests to normal and improved liver histology. The results of this study indicate that acyclovir is of no significant benefit in chronic HBeAg carriers with stable disease.
一项随机对照试验在30名HBeAg血清学阳性超过6个月的稳定HBsAg携带者中进行，比较了连续静脉输注阿昔洛韦（45mg/kg/天，共28天）与不进行其他治疗的效果。28名受试者在进入研究时血清中有乙肝病毒DNA聚合酶活性和/或乙肝病毒DNA。治疗没有显著的不良反应。12个月时，15名接受治疗的患者中有4名发生了HBeAg血清学转换为抗-HBe，其中1名还产生了抗-HBs，而未治疗组的15名患者中只有1名发生了转换（95%置信区间为12%和51%）。HBeAg血清学转换为抗-HBe伴随着血清肝功能检查恢复正常和肝脏组织学改善。这项研究的结果表明，阿昔洛韦对病情稳定的慢性HBeAg携带者没有显著益处。
